Clinical Trials
33 trialsNCT06806033 2026-05-26
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 2 Recruiting
NCT04844866 2026-04-29
DALY 2-EU
Miltenyi Biomedicine GmbH
Phase 2 Recruiting
NCT07554482 2026-04-28
Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma
Beijing Tongren Hospital
Phase 2 Not yet recruiting
NCT07365306 2026-04-24
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT04984837 2026-04-20
Study of Lacutamab in Peripheral T-cell Lymphoma
The Lymphoma Academic Research Organisation
Phase 2 Recruiting
NCT03418038 2026-04-16
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
NCT07451652 2026-04-01
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2 Recruiting
NCT07480850 2026-03-18
Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT06905509 2025-09-29
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
University of California, Davis
Phase 2 Recruiting
NCT07081022 2025-08-21
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Recruiting
NCT07001540 2025-06-19
Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
Fudan University
Phase 2 Recruiting
NCT06854445 2025-03-24
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Recruiting
NCT02692248 2024-10-10
Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Completed
NCT01626664 2024-04-25
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT04022005 2023-09-11
Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL
Sun Yat-sen University
Phase 2 Completed
NCT03422523 2022-08-22
ARGO
University Hospital Southampton NHS Foundation Trust
Phase 2 Terminated
NCT03488251 2022-08-16
PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
Molecular Templates, Inc.
Phase 2 Terminated
NCT05186558 2022-03-07
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05254899 2022-02-24
Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL
ChineseAMS
Phase 2 Unknown
NCT00436280 2020-08-06
Chemotherapy for Participants With Lymphoma
Eli Lilly and Company
Phase 2 Completed
NCT02918747 2020-01-28
PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage
Hunan Cancer Hospital
Phase 2 Unknown
NCT04239170 2020-01-23
Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma
Peking University
Phase 2 Unknown
NCT00166439 2020-01-14
Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma
Academic and Community Cancer Research United
Phase 2 Completed
NCT01670370 2019-02-15
Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT00336583 2018-06-26
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)
Asan Medical Center
Phase 2 Completed
NCT02533323 2018-05-09
P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens
Sun Yat-sen University
Phase 2 Terminated
NCT01562977 2017-10-30
RGemOx
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Completed
NCT02080234 2016-04-20
Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL
Sun Yat-sen University
Phase 2 Unknown
NCT01068392 2014-11-04
Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)
Dong-A University Hospital
Phase 2 Completed
NCT01307592 2014-01-10
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01921790 2013-08-22
Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma
Sun Yat-sen University
Phase 2 Unknown
NCT00006473 2013-01-23
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01019863 2011-01-12
LNH-RGDOX
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Phase 2 Unknown